Bio-Rad Laboratories Class A
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO and other ETFs, options, and stocks.About BIO
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments.
BIO Key Statistics
Stock Snapshot
With a market cap of 6.91B, Bio-Rad Laboratories Class A(BIO) trades at $256.56. The stock has a price-to-earnings ratio of 9.21.
On 2026-02-15, Bio-Rad Laboratories Class A(BIO) stock traded between a low of $246.00 and a high of $272.25. Shares are currently priced at $256.56, which is +4.3% above the low and -5.8% below the high.
Bio-Rad Laboratories Class A(BIO) shares are trading with a volume of 1.06M, against a daily average of 333.12K.
During the past year, Bio-Rad Laboratories Class A(BIO) stock moved between $211.43 at its lowest and $343.12 at its peak.
During the past year, Bio-Rad Laboratories Class A(BIO) stock moved between $211.43 at its lowest and $343.12 at its peak.
BIO News
Advertisement Recent trading in Bio-Rad Laboratories (BIO) has drawn attention after a series of negative returns over the past month and past 3 months, prompt...
Bio-Rad Laboratories ((BIO)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level...
In trading on Friday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) crossed below their 200 day moving average of $281.97, changing hands as low as $251.00 p...
Analyst ratings
57%
of 7 ratingsMore BIO News
Image source: The Motley Fool. Thursday, February 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Norman D. Schwartz President and Chief Oper...
The latest announcement is out from Bio-Rad Laboratories ( (BIO) ). Bio-Rad Laboratories reported financial results on February 12, 2026 for the fourth quarter...
Reports Q4 revenue $693.2M, consensus $687.71M. Norman Schwartz, Bio-Rad’s (BIO) Chief Executive Officer, stated: “2025 was a challenging year with geopolitical...
Bio-Rad Laboratories recently received AOAC International validation for its EZ-Check Listeria spp. Kit and EZ-Check Listeria monocytogenes Kit, which are desig...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.